Browsing Tag
Ovarian Cancer
35 posts
Biomarker promise or clinical reality: What ASPENOVA will prove or disprove
Can ASPENOVA validate biomarker-driven ovarian cancer therapy? Discover what Zentalis Pharmaceuticals, Inc.’s strategy means for the industry.
Can RNA-based cancer vaccines finally close the HRP ovarian cancer treatment gap?
Can RNA cancer vaccines close the ovarian cancer gap? Explore Epitopea’s strategy, risks, and what investors should watch next.
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Gilead Sciences (GILD) is buying Tubulis after Arcellx and Ouro. How aggressive is this deal spree getting?
Gilead is acquiring Tubulis for up to $5 billion to expand its ADC pipeline. Read what the deal means for oncology strategy, risk, and GILD stock.
Why Cyclin E1 biomarker targeting may become central to next-generation ovarian cancer therapies
Find out why Zentalis Pharmaceuticals’ Cyclin E1 strategy could reshape ovarian cancer treatment and investor sentiment into 2026.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
IMNN-001 plus PARP inhibitors shows extended survival in ovarian cancer. Find out what this means for IMUNON Inc. and future treatment strategies.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
KEYNOTE-B96 final analysis: Merck’s Keytruda cuts death risk by 18% in recurrent ovarian cancer across all-comer population
Merck's Keytruda cuts death risk 18% in platinum-resistant ovarian cancer regardless of PD-L1 status. FDA approved, EU opinion positive. Read the full analysis.